p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression - PubMed (original) (raw)
. 1992 Feb 1;52(3):674-9.
Affiliations
- PMID: 1346255
p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression
D Fults et al. Cancer Res. 1992.
Abstract
The human brain tumor, astrocytoma, typically progresses through three histopathologically defined stages with the passage of time: one premalignant stage, low-grade astrocytoma; and two malignant stages, anaplastic astrocytoma and glioblastoma multiforme. We correlated the results of a sequence analysis of the tumor suppressor gene, p53, and a restriction fragment length polymorphism analysis of chromosomes 17 and 10 in 45 patients with cerebral astrocytomas at different stages. To detect p53 mutations in tumor DNA, we analyzed polymerase chain reaction products corresponding to every p53-coding exon for single-strand conformation polymorphisms and confirmed the mutations by sequencing. Loss of heterozygosity (LOH) was determined by Southern transfer analysis of somatic and tumor DNA from these same patients using polymorphic markers for various loci on chromosomes 10 and 17. p53 mutations were found in 7 of 25 glioblastomas (28%), in 5 of 14 anaplastic astrocytomas (36%) but in 0 of 6 low-grade astrocytomas. p53 mutations were found in 62% of patients with LOH on chromosome 17p. These results indicated that p53 inactivation is a common genetic event in astrocytoma progression that may signal the transition from benign to malignant tumor stages. LOH on chromosome 10 was found in 61% of glioblastomas, in 23% of anaplastic astrocytomas, but in 0% of low-grade astrocytomas. LOH on chromosome 10 and p53 mutation were found together only in patients with glioblastoma multiforme (22%), suggesting that these genetic changes may accumulate during astrocytoma progression.
Similar articles
- Chromosome 10 and 17 deletions and p53 gene mutations in Thai patients with astrocytomas.
Put-Ti-Noi S, Petmitr S, Chanyavanich V, Sangruji T, Theerapuncharoen V, Hayashi K, Thangnipon W. Put-Ti-Noi S, et al. Oncol Rep. 2004 Jan;11(1):207-11. Oncol Rep. 2004. PMID: 14654927 - p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas.
Jin W, Xu X, Yang T, Hua Z. Jin W, et al. Chin Med J (Engl). 2000 Jul;113(7):662-6. Chin Med J (Engl). 2000. PMID: 11776043 - Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours.
Chattopadhyay P, Rathore A, Mathur M, Sarkar C, Mahapatra AK, Sinha S. Chattopadhyay P, et al. Oncogene. 1997 Aug 14;15(7):871-4. doi: 10.1038/sj.onc.1201238. Oncogene. 1997. PMID: 9266974 - Genetic alterations associated with glioma progression.
Kleihues P, Lübbe J, Watanabe K, von Ammon K, Ohgaki H. Kleihues P, et al. Verh Dtsch Ges Pathol. 1994;78:43-7. Verh Dtsch Ges Pathol. 1994. PMID: 7534015 Review. - Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, Abe H, Ishii N, Van Meir EG. Nozaki M, et al. Neuro Oncol. 1999 Apr;1(2):124-37. doi: 10.1093/neuonc/1.2.124. Neuro Oncol. 1999. PMID: 11550308 Free PMC article. Review.
Cited by
- TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy.
Noor H, Briggs NE, McDonald KL, Holst J, Vittorio O. Noor H, et al. Cancers (Basel). 2021 Oct 26;13(21):5362. doi: 10.3390/cancers13215362. Cancers (Basel). 2021. PMID: 34771529 Free PMC article. - Can Glycosylation Mask the Detection of MHC Expressing p53 Peptides by T Cell Receptors?
Nguyen TB, Lane DP, Verma CS. Nguyen TB, et al. Biomolecules. 2021 Jul 19;11(7):1056. doi: 10.3390/biom11071056. Biomolecules. 2021. PMID: 34356680 Free PMC article. - PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas.
Noorani I, de la Rosa J, Choi YH, Strong A, Ponstingl H, Vijayabaskar MS, Lee J, Lee E, Richard-Londt A, Friedrich M, Furlanetto F, Fuente R, Banerjee R, Yang F, Law F, Watts C, Rad R, Vassiliou G, Kim JK, Santarius T, Brandner S, Bradley A. Noorani I, et al. Genome Biol. 2020 Jul 30;21(1):181. doi: 10.1186/s13059-020-02092-2. Genome Biol. 2020. PMID: 32727536 Free PMC article. - Molecular cloning and expression of high GC-rich novel tumor suppressor gene HIC-1.
Kumar S. Kumar S. Mol Biotechnol. 2014 Nov;56(11):1040-8. doi: 10.1007/s12033-014-9783-8. Mol Biotechnol. 2014. PMID: 25001210 - Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A. Ohka F, et al. Tumour Biol. 2014 Jun;35(6):5911-20. doi: 10.1007/s13277-014-1784-5. Epub 2014 Mar 5. Tumour Biol. 2014. PMID: 24590270
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous